Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancer

Imagem de Miniatura
Arquivos
art_ELIAS_Epithelial_cells_captured_from_ductal_carcinoma_in_situ_2016.PDF (2.45 MB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IMPACT JOURNALS LLC
Autores
ELIAS, Eliana Vanina
CASTRO, Nadia Pereira de
PINEDA, Paulo Henrique Baldan
ABUAZAR, Carolina Sens
OSORIO, Cynthia Aparecida Bueno de Toledo
PINILLA, Mabel Gigliola
SILVA, Sabrina Daniela da
CAMARGO, Anamaria Aranha
SILVA JR., Wilson Araujo
FERREIRA, Elisa Napolitano e
Citação
ONCOTARGET, v.7, n.46, p.75672-75684, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Breast cancer biomarkers that can precisely predict the risk of progression of non-invasive ductal carcinoma in situ (DCIS) lesions to invasive disease are lacking. The identification of molecular alterations that occur during the invasion process is crucial for the discovery of drivers of transition to invasive disease and, consequently, biomarkers with clinical utility. In this study, we explored differences in gene expression in mammary epithelial cells before and after the morphological manifestation of invasion, i.e., early and late stages, respectively. In the early stage, epithelial cells were captured from both pre-invasive lesions with distinct malignant potential [pure DCIS as well as the in situ component that co-exists with invasive breast carcinoma lesions (DCIS-IBC)]; in the late stage, epithelial cells were captured from the two distinct morphological components of the same sample (in situ and invasive components). Candidate genes were identified using cDNA microarray and rapid subtractive hybridization (RaSH) cDNA libraries and validated by RT-qPCR assay using new samples from each group. These analyses revealed 26 genes, including 20 from the early and 6 from the late stage. The expression profile based on the 20 genes, marked by a preferential decrease in expression level towards invasive phenotype, discriminated the majority of DCIS samples. Thus, this study revealed a gene expression signature with the potential to predict DCIS progression and, consequently, provides opportunities to tailor treatments for DCIS patients.
Palavras-chave
breast cancer, ductal carcinoma in situ progression, gene signature, cellular-based analysis, molecular markers
URI
https://observatorio.fm.usp.br/handle/OPI/18002
Referências
  1. Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899
  2. Acs G, 2001, CANCER RES, V61, P3561
  3. Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
  4. Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9
  5. Benjamin DI, 2014, ACS CHEM BIOL, V9, P1340, DOI 10.1021/cb5001907
  6. Brentani RR, 2005, CRIT REV ONCOL HEMAT, V54, P95, DOI 10.1016/j.critrevonc.2004.12.006
  7. Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
  8. Castro NP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2157
  9. Collins LC, 2005, CANCER-AM CANCER SOC, V103, P1778, DOI 10.1002/cncr.20979
  10. Erbas B, 2006, BREAST CANCER RES TR, V97, P135, DOI 10.1007/s10549-005-9101-z
  11. Ferreira EN, 2010, DIAGN MOL PATHOL, V19, P45, DOI 10.1097/PDM.0b013e3181ae8186
  12. Forsti A, 2007, BREAST CANCER RES TR, V101, P83, DOI 10.1007/s10549-006-9265-1
  13. Folgueira MAAK, 2005, CLIN CANCER RES, V11, P7434
  14. Gauger KJ, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-11
  15. Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
  16. Hannemann J, 2006, BREAST CANCER RES, V8, P61, DOI 10.1186/BCR1613
  17. Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19
  18. Hernandez L, 2012, J PATHOL, V227, P42, DOI 10.1002/path.3990
  19. Hsu TH, 2015, CELL DEATH DIFFER, V22, P801, DOI 10.1038/cdd.2014.175
  20. Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745
  21. Hui LJ, 2007, CELL CYCLE, V6, P2429
  22. Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297
  23. Kalles V, 2012, TUMOR BIOL, V33, P1231, DOI 10.1007/s13277-012-0371-x
  24. Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371
  25. Knudsen ES, 2012, BREAST CANCER RES TR, V133, P1009, DOI 10.1007/s10549-011-1894-3
  26. Lee RJ, 2012, INT J SURG ONCOL, V2012, DOI 10.1155/2012/123549
  27. Leonard GD, 2004, J NATL CANCER I, V96, P906, DOI 10.1093/jnci/djh164
  28. Leygue E, 2000, J PATHOL, V192, P313
  29. LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287
  30. Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
  31. Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
  32. Malanchi I, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-SY28-02
  33. Maschietto M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.105
  34. Maschietto M, 2011, EUR J CANCER, V47, P2715, DOI 10.1016/j.ejca.2011.05.024
  35. McAuliffe PF, 2010, CLIN BREAST CANCER, V10, pS59, DOI 10.3816/CBC.2010.s.013
  36. McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676
  37. Milde-Langosch K, 2005, BRIT J CANCER, V92, P2206, DOI 10.1038/sj.bjc.6602655
  38. Morrow M, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv290
  39. Muggerud AA, 2010, MOL ONCOL, V4, P357, DOI 10.1016/j.molonc.2010.06.007
  40. Nagaraja GM, 2006, ONCOGENE, V25, P2328, DOI 10.1038/sj.onc.1209265
  41. Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
  42. Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
  43. Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
  44. Porter D, 2003, MOL CANCER RES, V1, P362
  45. Saeed AI, 2003, BIOTECHNIQUES, V34, P374
  46. Schnitt SJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2228
  47. Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610
  48. Sens-Abuazar C, 2012, TRANSL ONCOL, V5, P113, DOI 10.1593/tlo.11280
  49. Sgroi DC, 1999, CANCER RES, V59, P5656
  50. Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004
  51. STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616
  52. Tezuka N, 2007, BIOCHEM BIOPH RES CO, V356, P648, DOI 10.1016/j.bbrc.2007.03.019
  53. Tiwari N, 2013, PLOS ONE, V8
  54. Trost N, 2013, INT J MOL MED, V31, P717, DOI 10.3892/ijmm.2013.1231
  55. Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465
  56. Virnig Beth A, 2009, Evid Rep Technol Assess (Full Rep), P1
  57. Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
  58. Yoon H-J, 2002, CURRENT BIOL
  59. Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484
  60. Zajchowski DA, 2001, CANCER RES, V61, P5168

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - ODS/03